Price
CHART BY
Frequently asked questions
What is Outlook's market capitalization?
The market capitalization of Outlook is $78.85M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Outlook?
Outlook's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.431. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Outlook's stock?
Currently, 4 analysts cover Outlook's stock, with a consensus target price of $10.75. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Outlook?
Outlook's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$76.32M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Outlook?
Outlook has a free cash flow of -$64.05M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Outlook have, and what sector and industry does it belong to?
Outlook employs approximately 23 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Outlook's shares?
The free float of Outlook is 26.95M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $78.85M
- EPS (TTM)
- -$1.431
- Free Float
- 26.95M
- EBITDA (TTM)
- -$76.32M
- Free Cashflow (TTM)
- -$64.05M
Pricing
- 1D span
- $1.696$1.891
- 52W span
- $0.87$9.24
Analyst Ratings
The price target is $10.75 and the stock is covered by 4 analysts.
Buy
3
Hold
1
Sell
0
Information
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
- Employees
- 23
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US69012T3059
- Primary Ticker
- OTLK
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet